<DOC>
	<DOCNO>NCT02720783</DOCNO>
	<brief_summary>The primary objective study evaluate local tolerability new Econazole/Benzydamine pessary , comparison Econazole Benzydamine stand-alone product placebo . Pharmacokinetics study product single multiple application o.d . 3 day , overall local general tolerability , safety comfort use also evaluate .</brief_summary>
	<brief_title>Tolerability Pharmacokinetic Study Econazole Nitrate Plus Benzydamine HCl Vaginal Pessary</brief_title>
	<detailed_description />
	<mesh_term>Benzydamine</mesh_term>
	<mesh_term>Econazole</mesh_term>
	<criteria>1 . Informed consent : sign write informed consent inclusion study . 2 . Sex age : healthy woman , age 1855 year old inclusive . 3 . Body Mass Index ( BMI ) : 18.530 kg/m2 inclusive . 4 . Vital sign : systolic blood pressure 100139 mmHg , diastolic blood pressure 5089 mmHg , heart rate 5090 bpm , measure 5 min rest ( sit position ) . 5 . Full comprehension : ability comprehend full nature purpose study , include possible risk side effect ; ability cooperate Investigator comply requirement entire study . 6 . Sexual abstinence : agreement sexual abstinence study . 7 . Contraception fertility : woman childbearing potential , even sexually abstinent study require study inclusion criterion , must use least one reliable method contraception , follow : 1. hormonal oral , implantable , transdermal , injectable contraceptive least 2 month screen visit ; 2. nonhormonal intrauterine device [ IUD ] least 2 month screen visit ; 3. male sexual partner agree use male condom ; 4. vasectomise sexual partner . Female participant nonchildbearing potential admit . For female subject , pregnancy test result must negative screen day 1 . 8 . PAP test : negative PAP test result ( i.e . normal PAP test result without atypical cell ) screen . 1 . ECG ( 12leads , supine position ) : clinically significant abnormality . 2 . Physical finding : clinically significant abnormal physical finding could interfere objective study judge Investigator . 3 . Laboratory analysis : clinically significant abnormal laboratory value indicative physical illness . 4 . Allergies : ascertain presumptive hypersensitivity ( include allergy ) active ingredient ( econazole nitrate and/or benzydamine HCl ) and/or formulation ' excipients related drug , e.g . azoles ; history anaphylaxis drug allergic reaction general , Investigator considers may affect outcome study . 5 . Diseases : relevant history renal , hepatic , gastrointestinal , genitourinary , cardiovascular , respiratory , skin , haematological , endocrine neurological disease may interfere aim study affect subject 's safety . 6 . Genitourinary disease : presence specific genitourinary symptom detect visit 2 relevant questionnaire ( genitourinary symptom questionnaire ) . 7 . Infection history : history bacterial urinary tract bacterial fungal vaginal infection 3 week screen visit . 8 . Systemic and/or local infection : bacterial fungal infection may interfere aim study affect subject 's safety . If result microbiological analysis concern Ureaplasma/Mycoplasma Actinomyces positive , subject enrol asymptomatic without clinical evidence ( gynaecological visit , PAP test vaginal pH measurement ) vaginal infection . 9 . Gynaecological finding : clinically significant abnormal finding gynaecological visit perform study Gynaecologist . 10 . Mucosa condition : alter mucosa condition affect site insertion ( e.g . open lesion ) . 11 . Habits : use vaginal detergent , soap wash , Investigator 's opinion , may influence vaginal pH and/or change vaginal flora . 12 . Medications : medication ( topical systemic ) , include counter , herbal medication , topical drug application area , anticoagulant , warfarin , acenocoumarol rivaroxaban , 2 week start study . Hormonal contraceptives hormonal replacement therapy allow . Paracetamol allow countermeasure adverse event , case case basis , deem appropriate Investigator . 13 . Investigative drug study : participation evaluation drug 3 month study , calculate first day month follow last visit previous study first day present study ( date inform consent signature ) . 14 . Blood donation : blood donation 3 month study . 15 . Drug , alcohol , caffeine , tobacco : history drug , alcohol ( &gt; 1 drink/day , define accord USDA Dietary Guidelines 2010 ) , tobacco ( â‰¥ 10 cigarettes/day ) caffeine ( &gt; 5 cup coffee/tea/day ) abuse . 16 . Diet : Abnormal diet ( &lt; 1600 &gt; 3500 kcal/day ) substantial change eat habit 4 week study ; vegetarian . 17 . Pregnancy : positive miss pregnancy test screen day 1 , pregnant lactate woman female childbearing potential follow adequate contraceptive procedure . 18 . Noncompliance : subject suspect high potential noncompliance study procedure accord Investigator 's judgement , include noncompliance sexual abstinence study . 19 . Drug test ( cocaine , amphetamine , methamphetamine , cannabinoids , opiates ecstasy ) : positive result drug test screening . 20 . Alcohol test : positive alcohol breath test day 1 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Econazole nitrate 150mg</keyword>
	<keyword>Benzydamine HCl 6mg</keyword>
	<keyword>Vaginal pessary</keyword>
	<keyword>Tolerability</keyword>
</DOC>